PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to explore the prognostic values of routine pre-treatment hematological parameters in patients with nasopharyngeal carcinoma (NPC).
UNASSIGNED: The hematological parameters and clinical data of patients with NPC were collected from January 2012 to December 2013 at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The survival statistics were obtained by regularly following-up the patients. The cut-off values for the hematological parameters were calculated using X-tile software. SPSS version 24.0 was used for the statistical analysis. The relationship between the hematological parameters and the prognosis of patients with NPC was analyzed using the Kaplan-Meier method and Cox multivariate regression. The discriminating abilities of the factors, which predict the prognosis, were evaluated by utilizing the receiver operating characteristic (ROC) area under the curve (AUC).
UNASSIGNED: This study included 179 patients with NPC. Multivariate analysis shows that pretreatment platelet-to-lymphocyte ratio (PLR; hazard ratio; HR = 0.44, 95% CI [0.21-0.91], p = 0.029), serum albumin (ALB; HR = 2.49, 95% CI [1.17-5.30], p = 0.018), and globulin (GLO; HR = 0.44, 95% CI [0.21-0.90], p = 0.024) are independent predictors for 5-year overall survival (OS) in patients with NPC. In addition, pre-treatment PLR (HR = 0.47, 95% CI [0.25-0.90], p = 0.022) and pre-treatment GLO (HR = 0.37, 95% CI [0.19-0.72], p = 0.001) are associated with 5-year progression-free survival (PFS) in patients with NPC. Based on the results of the multivariate analysis, we proposed a new biomarker GLO-PLR, which is observably correlated with the T stage, N stage and clinical stage in patients with NPC. The OS resolving ability of the GLO-PLR evaluated by AUC is 0.714, which is better than those of GLO and PLR. The PFS resolving ability of the GLO-PLR evaluated by AUC was 0.696, which is also better than those of GLO and PLR.
UNASSIGNED: Pre-treatment PLR, ALB, and GLO are independent predictors of 5-year OS in patients with NPC, where PLR and GLO are also independent predictors of 5-year FPS. Compared with other hematological parameters, the proposed GLO-PLR is an inexpensive, effective, objective, and easy-to-measure marker for predicting the prognosis of NPC.
UNASSIGNED: The hematological parameters and clinical data of patients with NPC were collected from January 2012 to December 2013 at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The survival statistics were obtained by regularly following-up the patients. The cut-off values for the hematological parameters were calculated using X-tile software. SPSS version 24.0 was used for the statistical analysis. The relationship between the hematological parameters and the prognosis of patients with NPC was analyzed using the Kaplan-Meier method and Cox multivariate regression. The discriminating abilities of the factors, which predict the prognosis, were evaluated by utilizing the receiver operating characteristic (ROC) area under the curve (AUC).
UNASSIGNED: This study included 179 patients with NPC. Multivariate analysis shows that pretreatment platelet-to-lymphocyte ratio (PLR; hazard ratio; HR = 0.44, 95% CI [0.21-0.91], p = 0.029), serum albumin (ALB; HR = 2.49, 95% CI [1.17-5.30], p = 0.018), and globulin (GLO; HR = 0.44, 95% CI [0.21-0.90], p = 0.024) are independent predictors for 5-year overall survival (OS) in patients with NPC. In addition, pre-treatment PLR (HR = 0.47, 95% CI [0.25-0.90], p = 0.022) and pre-treatment GLO (HR = 0.37, 95% CI [0.19-0.72], p = 0.001) are associated with 5-year progression-free survival (PFS) in patients with NPC. Based on the results of the multivariate analysis, we proposed a new biomarker GLO-PLR, which is observably correlated with the T stage, N stage and clinical stage in patients with NPC. The OS resolving ability of the GLO-PLR evaluated by AUC is 0.714, which is better than those of GLO and PLR. The PFS resolving ability of the GLO-PLR evaluated by AUC was 0.696, which is also better than those of GLO and PLR.
UNASSIGNED: Pre-treatment PLR, ALB, and GLO are independent predictors of 5-year OS in patients with NPC, where PLR and GLO are also independent predictors of 5-year FPS. Compared with other hematological parameters, the proposed GLO-PLR is an inexpensive, effective, objective, and easy-to-measure marker for predicting the prognosis of NPC.
摘要：
■本研究旨在探讨鼻咽癌（NPC）患者常规治疗前血液学参数的预后价值。
■收集2012年1月至2013年12月同济医院鼻咽癌患者血液学指标及临床资料，同济医学院,华中科技大学.通过定期随访获得患者的生存统计数据。使用X-tile软件计算血液学参数的截止值。采用SPSS24.0版进行统计分析。采用Kaplan-Meier法和Cox多因素回归分析血液学参数与鼻咽癌患者预后的关系。因素的辨别能力，预测预后，通过利用受试者工作特征（ROC）曲线下面积（AUC）进行评估。
■这项研究包括179名鼻咽癌患者。多因素分析显示，治疗前血小板与淋巴细胞比值（PLR；风险比；HR=0.44，95%CI[0.21-0.91]，p=0.029),血清白蛋白（ALB；HR=2.49，95%CI[1.17-5.30]，p=0.018),和球蛋白（GLO；HR=0.44，95%CI[0.21-0.90]，p=0.024）是NPC患者5年总生存率（OS）的独立预测因子。此外,治疗前PLR（HR=0.47，95%CI[0.25-0.90]，p=0.022)和预处理GLO(HR=0.37，95%CI[0.19-0.72]，p=0.001）与NPC患者的5年无进展生存期（PFS）相关。根据多变量分析的结果，我们提出了一种新的生物标志物GLO-PLR，这与T阶段相关，NPC患者的N分期和临床分期。AUC评估的GLO-PLR的OS分辨能力为0.714，优于GLO和PLR。AUC评估的GLO-PLR的PFS分辨能力为0.696，也优于GLO和PLR。
■预处理PLR，ALB,和GLO是NPC患者5年OS的独立预测因子，其中PLR和GLO也是5年FPS的独立预测因子。与其他血液学参数相比，拟议的GLO-PLR是一种廉价的，有效,目标,和易于测量的指标预测NPC的预后。
■收集2012年1月至2013年12月同济医院鼻咽癌患者血液学指标及临床资料，同济医学院,华中科技大学.通过定期随访获得患者的生存统计数据。使用X-tile软件计算血液学参数的截止值。采用SPSS24.0版进行统计分析。采用Kaplan-Meier法和Cox多因素回归分析血液学参数与鼻咽癌患者预后的关系。因素的辨别能力，预测预后，通过利用受试者工作特征（ROC）曲线下面积（AUC）进行评估。
■这项研究包括179名鼻咽癌患者。多因素分析显示，治疗前血小板与淋巴细胞比值（PLR；风险比；HR=0.44，95%CI[0.21-0.91]，p=0.029),血清白蛋白（ALB；HR=2.49，95%CI[1.17-5.30]，p=0.018),和球蛋白（GLO；HR=0.44，95%CI[0.21-0.90]，p=0.024）是NPC患者5年总生存率（OS）的独立预测因子。此外,治疗前PLR（HR=0.47，95%CI[0.25-0.90]，p=0.022)和预处理GLO(HR=0.37，95%CI[0.19-0.72]，p=0.001）与NPC患者的5年无进展生存期（PFS）相关。根据多变量分析的结果，我们提出了一种新的生物标志物GLO-PLR，这与T阶段相关，NPC患者的N分期和临床分期。AUC评估的GLO-PLR的OS分辨能力为0.714，优于GLO和PLR。AUC评估的GLO-PLR的PFS分辨能力为0.696，也优于GLO和PLR。
■预处理PLR，ALB,和GLO是NPC患者5年OS的独立预测因子，其中PLR和GLO也是5年FPS的独立预测因子。与其他血液学参数相比，拟议的GLO-PLR是一种廉价的，有效,目标,和易于测量的指标预测NPC的预后。
